Janssen-Cilag A.G., Switzerland

Clinical trials sponsored by Janssen-Cilag A.G., Switzerland, explained in plain language.

Now part of Johnson & Johnson JNJ NYSE

Swiss affiliate of Johnson & Johnson's pharmaceutical division.

Not investment advice. Company information is shown for context only. Clinical trials frequently fail.

Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.

Trials to join now! 1

New study tracks how long guselkumab lasts for IBD patients

Disease control Recruiting now

This study follows 50 people with moderate to severe Crohn's disease or ulcerative colitis to see how long they stay on guselkumab in real-world settings. Researchers will measure treatment persistence and early symptom improvements using patient diaries. The goal is to understan…

Sponsor: Janssen-Cilag A.G., Switzerland • Aim: Disease control

Last updated Jun 27, 2026 13:07 UTC

Janssen-Cilag A.G., Switzerland

New study tracks how long guselkumab lasts for IBD patients